Predominance of positive epistasis among drug resistance-associated mutations in HIV-1 protease
暂无分享,去创建一个
A. Chakraborty | R. Sun | J. Lloyd-Smith | Yushen Du | J. Barton | Lei Dai | Tian-hao Zhang | Yuxiang Tan | Wenwen Pang
[1] R. Levy,et al. Epistasis and entrenchment of drug resistance in HIV-1 subtype B , 2019, eLife.
[2] C. Schiffer,et al. Constrained mutational sampling of amino acids in HIV-1 protease evolution , 2018, bioRxiv.
[3] Matthew R. McKay,et al. Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies , 2018, Proceedings of the National Academy of Sciences.
[4] R. Detels,et al. Effects of Mutations on Replicative Fitness and Major Histocompatibility Complex Class I Binding Affinity Are Among the Determinants Underlying Cytotoxic-T-Lymphocyte Escape of HIV-1 Gag Epitopes , 2017, mBio.
[5] M. Wainberg,et al. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. , 2017, Virus research.
[6] R. Levy,et al. Potts Hamiltonian models of protein co-variation, free energy landscapes, and evolutionary fitness. , 2017, Current opinion in structural biology.
[7] Martin Weigt,et al. Large-scale identification of coevolution signals across homo-oligomeric protein interfaces by direct coupling analysis , 2017, Proceedings of the National Academy of Sciences.
[8] Ryan D. Hernandez,et al. Functional Segregation of Overlapping Genes in HIV , 2016, Cell.
[9] J. Mugisha,et al. Estimation of the HIV-1 backward mutation rate from transmitted drug-resistant strains , 2016, Theoretical population biology.
[10] R. Sun,et al. Quantifying the evolutionary potential and constraints of a drug-targeted viral protein , 2016 .
[11] R. Levy,et al. Inference of Epistatic Effects Leading to Entrenchment and Drug Resistance in HIV-1 Protease , 2016, bioRxiv.
[12] Tyler N. Starr,et al. Epistasis in protein evolution , 2016, Protein science : a publication of the Protein Society.
[13] J. O'Neill,et al. Tackling drug-resistant infections globally: final report and recommendations , 2016 .
[14] Dmitry Chudakov,et al. Local fitness landscape of the green fluorescent protein , 2016, Nature.
[15] B. Walker,et al. Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable , 2016, Nature Communications.
[16] James O Lloyd-Smith,et al. Adaptation in protein fitness landscapes is facilitated by indirect paths , 2016, bioRxiv.
[17] Simona Cocco,et al. ACE: adaptive cluster expansion for maximum entropy graphical model inference , 2016, bioRxiv.
[18] Tara L. Kieffer,et al. Hepatitis C virus drug resistance–associated substitutions: State of the art summary , 2015, Hepatology.
[19] R. Sanjuán,et al. Extremely High Mutation Rate of HIV-1 In Vivo , 2015, PLoS biology.
[20] A. Chakraborty,et al. Identification of drug resistance mutations in HIV from constraints on natural evolution. , 2015, Physical review. E.
[21] L. James,et al. HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry , 2015, Journal of Virology.
[22] Yuan Chu,et al. HIV protease inhibitors: a review of molecular selectivity and toxicity , 2015, HIV/AIDS.
[23] Zhiqiang Tan,et al. Deep Sequencing of Protease Inhibitor Resistant HIV Patient Isolates Reveals Patterns of Correlated Mutations in Gag and Protease , 2015, PLoS Comput. Biol..
[24] Huldrych F. Günthard,et al. Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds , 2015, PLoS pathogens.
[25] Jun Lin,et al. Mechanisms of antibiotic resistance , 2015, Front. Microbiol..
[26] R. Sun,et al. High-throughput profiling of point mutations across the HIV-1 genome , 2014, Retrovirology.
[27] M. Webber,et al. Molecular mechanisms of antibiotic resistance , 2014, Nature Reviews Microbiology.
[28] Nicholas C. Wu,et al. A Comprehensive Biophysical Description of Pairwise Epistasis throughout an Entire Protein Domain , 2014, Current Biology.
[29] Claudia Bank,et al. A systematic survey of an intragenic epistatic landscape , 2014, bioRxiv.
[30] John P. Barton,et al. The Fitness Landscape of HIV-1 Gag: Advanced Modeling Approaches and Validation of Model Predictions by In Vitro Testing , 2014, PLoS Comput. Biol..
[31] M. Parera,et al. Strong epistatic interactions within a single protein. , 2014, Molecular biology and evolution.
[32] Cécile Viboud,et al. Spatial Transmission of 2009 Pandemic Influenza in the US , 2014, PLoS Comput. Biol..
[33] Joshua B. Plotkin,et al. Contingency and entrenchment in protein evolution under purifying selection , 2014, Proceedings of the National Academy of Sciences.
[34] R. Sun,et al. A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity , 2014, PLoS pathogens.
[35] Andrew L. Ferguson,et al. Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. , 2013, Immunity.
[36] M. Wainberg,et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure , 2013, Retrovirology.
[37] J. Draghi,et al. SELECTION BIASES THE PREVALENCE AND TYPE OF EPISTASIS ALONG ADAPTIVE TRAJECTORIES , 2012, Evolution; international journal of organic evolution.
[38] M. Götte,et al. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance. , 2012, Current opinion in virology.
[39] Martin A. Nowak,et al. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome , 2012, Nature Medicine.
[40] B. Torbett,et al. Accessory mutations maintain stability in drug-resistant HIV-1 protease. , 2011, Journal of molecular biology.
[41] I. Gordo,et al. Pervasive Sign Epistasis between Conjugative Plasmids and Drug-Resistance Chromosomal Mutations , 2011, PLoS genetics.
[42] R. Lenski,et al. Negative Epistasis Between Beneficial Mutations in an Evolving Bacterial Population , 2011, Science.
[43] S. Borrell,et al. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[44] Sebastian Bonhoeffer,et al. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase , 2011, Nature Genetics.
[45] D. Baker,et al. Role of conformational sampling in computing mutation‐induced changes in protein structure and stability , 2011, Proteins.
[46] M. Wainberg,et al. RIG-I-Mediated Antiviral Signaling Is Inhibited in HIV-1 Infection by a Protease-Mediated Sequestration of RIG-I , 2010, Journal of Virology.
[47] R. Shafer,et al. HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance , 2010, Antimicrobial Agents and Chemotherapy.
[48] L. Du,et al. Global fitness profiling of fission yeast deletion strains by barcode sequencing , 2010, Genome Biology.
[49] Sebastian Bonhoeffer,et al. Compensation of Fitness Costs and Reversibility of Antibiotic Resistance Mutations , 2010, Antimicrobial Agents and Chemotherapy.
[50] Diarmaid Hughes,et al. Antibiotic resistance and its cost: is it possible to reverse resistance? , 2010, Nature Reviews Microbiology.
[51] Y. Li,et al. Prevalent positive epistasis in E. coli and S. cerevisiae metabolic networks , 2009, Nature Genetics.
[52] A. Camilli,et al. Tn-seq; high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms , 2009, Nature Methods.
[53] Bonaventura Clotet,et al. Epistasis among deleterious mutations in the HIV-1 protease. , 2009, Journal of molecular biology.
[54] A. Sousa,et al. Positive Epistasis Drives the Acquisition of Multidrug Resistance , 2009, PLoS genetics.
[55] H. Kräusslich,et al. Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss , 2009, PLoS pathogens.
[56] Michael Monsour,et al. Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.
[57] Zhijian Lu. Second generation HIV protease inhibitors against resistant virus , 2008, Expert opinion on drug discovery.
[58] David Heckerman,et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients , 2008, The Journal of experimental medicine.
[59] Yves Moreau,et al. Modelled in vivo HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response , 2008, Antiviral therapy.
[60] Tony Vangeneugden,et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. , 2008, AIDS research and human retroviruses.
[61] F. Maggiolo,et al. Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients , 2007, HIV clinical trials.
[62] L. Chao,et al. Understanding the Evolutionary Fate of Finite Populations: The Dynamics of Mutational Effects , 2007, PLoS biology.
[63] W. Heneine,et al. The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions , 2006, Journal of Virology.
[64] Dan S. Tawfik,et al. Robustness–epistasis link shapes the fitness landscape of a randomly drifting protein , 2006, Nature.
[65] Bonaventura Clotet,et al. HIV-1 Protease Catalytic Efficiency Effects Caused by Random Single Amino Acid Substitutions , 2006, Molecular biology and evolution.
[66] R. Shafer. Rationale and uses of a public HIV drug-resistance database. , 2006, The Journal of infectious diseases.
[67] C. Petropoulos,et al. Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. , 2006, AIDS research and human retroviruses.
[68] Thomas Lengauer,et al. Improved Prediction of Response to Antiretroviral Combination Therapy using the Genetic Barrier to Drug Resistance , 2006, Antiviral therapy.
[69] Rebecca Hoh,et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. , 2005, The Journal of infectious diseases.
[70] Klaus Korn,et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.
[71] P. Harrigan,et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. , 2005, The Journal of infectious diseases.
[72] C. Petropoulos,et al. Evidence for Positive Epistasis in HIV-1 , 2004, Science.
[73] D. Roze,et al. Epistasis in RNA Viruses , 2004, Science.
[74] Rafael Sanjuán,et al. The contribution of epistasis to the architecture of fitness in an RNA virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[75] M. Segal,et al. Persistence of primary drug resistance among recently HIV-1 infected adults , 2004, AIDS.
[76] Matthew J. Gonzales,et al. Distribution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Mutation Patterns in 4,183 Persons Undergoing Genotypic Resistance Testing , 2004, Antimicrobial Agents and Chemotherapy.
[77] D. Andersson,et al. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. , 2004, Research in microbiology.
[78] D. Bangsberg,et al. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. , 2004, The Journal of antimicrobial chemotherapy.
[79] Christopher J. Lee,et al. Positive Selection Detection in 40,000 HumanImmunodeficiency Virus (HIV) Type 1 Sequences Automatically IdentifiesDrug Resistance and Positive Fitness Mutations in HIV Proteaseand ReverseTranscriptase , 2004, Journal of Virology.
[80] Hui Zhang,et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA , 2003, Nature.
[81] Gersende Caron,et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.
[82] M. Malim,et al. DNA Deamination Mediates Innate Immunity to Retroviral Infection , 2003, Cell.
[83] M. Gougeon,et al. Cell death and immunity: Apoptosis as an HIV strategy to escape immune attack , 2003, Nature Reviews Immunology.
[84] M. Segal,et al. Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected Adults , 2002, Journal of Virology.
[85] Ursula Rothlisberger,et al. Drug resistance in HIV‐1 protease: Flexibility‐assisted mechanism of compensatory mutations , 2002, Protein science : a publication of the Protein Society.
[86] D. Kontoyiannis,et al. Antifungal drug resistance of pathogenic fungi , 2002, The Lancet.
[87] Bluma G. Brenner,et al. Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection , 2002, Journal of Virology.
[88] J. E. Hyde,et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? , 2001, Trends in parasitology.
[89] H. Guyatt. Bednet benefits blighted by poor coverage , 2001 .
[90] M. Johnson,et al. Replicative fitness in vivo of HIV‐1 variants with multiple drug resistance‐associated mutations , 2001, Journal of medical virology.
[91] A. Velázquez‐Campoy,et al. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. , 2001, Archives of biochemistry and biophysics.
[92] R. Grant,et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus , 2001, Nature Medicine.
[93] C. Cameron,et al. RNA virus error catastrophe: Direct molecular test by using ribavirin , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[94] R Hoh,et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.
[95] Pedro R. Lowenstein,et al. Response of Foot-and-Mouth Disease Virus to Increased Mutagenesis: Influence of Viral Load and Fitness in Loss of Infectivity , 2000, Journal of Virology.
[96] R. Myers,et al. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. , 2000, AIDS research and human retroviruses.
[97] S. Frost,et al. Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: the Relative Roles of Drift and Selection , 2000, Journal of Virology.
[98] J. McKimm-Breschkin,et al. Resistance of influenza viruses to neuraminidase inhibitors--a review. , 2000, Antiviral research.
[99] C. Boucher,et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. , 1999, AIDS.
[100] Santiago F. Elena,et al. Little Evidence for Synergism Among Deleterious Mutations in a Nonsegmented RNA Virus , 1999, Journal of Molecular Evolution.
[101] B. Levin,et al. The biological cost of antibiotic resistance. , 1999, Current opinion in microbiology.
[102] S. Yerly,et al. Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.
[103] J. Martinez-Picado,et al. Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.
[104] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[105] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[106] J. Perfect,et al. Antifungal Resistance Trends Towards the Year 2000 , 1997, Drugs.
[107] B. Korant,et al. Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[108] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[109] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[110] E. D. Weinberger,et al. Fourier and Taylor series on fitness landscapes , 1991, Biological Cybernetics.
[111] K Bebenek,et al. The accuracy of reverse transcriptase from HIV-1. , 1988, Science.
[112] D. Liberles,et al. Evolution in the light of fitness landscape theory. , 2019, Trends in ecology & evolution.
[113] McKimm,et al. Resistance of influenza viruses to neuraminidase inhibitors — a review , 2000 .
[114] J. Perfect,et al. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. , 1997, Drugs.